Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025
Rhea-AI Summary
Elite Pharmaceuticals (OTCQB: ELTP) will release its second quarter fiscal 2026 financial results for the period ended September 30, 2025 on Friday, November 14, 2025. Management will host a live conference call on Monday, November 17, 2025 at 11:30 AM EST to review financial and operating results and provide a business update. Stockholders are encouraged to submit questions in advance by the stated deadlines.
Call details: domestic dial-in 1-800-346-7359, international 1-973-528-0008, conference number 98840. Audio replay will be available at https://elite.irpass.com/events_presentations.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ELTP gained 0.84%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Financials for Second Quarter of Fiscal Year 2026 Ended September 30, 2025 will be released on Friday, November 14, 2025
Northvale, New Jersey--(Newsfile Corp. - November 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2026 fiscal year will be released on Friday, November 14, 2025. Elite's management will host a live conference call on Monday, November 17th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Stockholders should submit their questions to the company prior to the call.
| Date: | November 17, 2025 |
| Time: | 11:30 AM EST |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com General questions by 5:00 PM EST on Thursday, November 13, 2025 Financial questions by 7:00 PM EST on Friday, November 14, 2025 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Elite's product lines consist of immediate-release and controlled-release, solid oral dose products, which are marketed under the Elite Laboratories label, as well as pursuant to licenses granted to third-party pharmaceutical marketing and distribution organizations. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273653
FAQ
When will Elite Pharmaceuticals (ELTP) release Q2 fiscal 2026 results?
When and at what time is the Elite Pharmaceuticals (ELTP) conference call?
How can shareholders submit questions for the ELTP November 17, 2025 call?
What dial-in numbers and conference ID do I use for the ELTP call on November 17, 2025?
Where can I listen to the audio replay of Elite Pharmaceuticals' November 17, 2025 call?
